Abstract:BACKGROUND: Plasma circulating tumor DNA (ctDNA) may be a surrogate, minimally invasive approach to tissue-based epidermal growth factor receptor (EGFR) mutation detection in non-small cell lung cancer (NSCLC) patients. However, the predictive ability of preoperative ctDNA EGFR mutation test on long-term postoperative survival and tumor metastasis development has not been extensively investigated.METHODS: Stage I-III NSCLC patients with tissue EGFR mutations were enrolled in this study (n=174). The ctDNA EGFR mutations were identified in paired preoperative plasma samples. EGFR mutation testing was performed using Scorpion amplified refractory mutation system (ARMS) technology. The correlation between ctDNA EGFR mutation status and clinicopathologic parameters was analyzed. By combining at least 5 years of follow-up data, we assessed the relationship between ctDNA EGFR mutation status and disease-free survival (DFS) and overall survival (OS).RESULTS: Plasma-based ctDNA EGFR mutations were detected in 27 patients. The mutation types were exactly matched with those in paired tissue samples. Blood test sensitivity was closely associated with N stages, tumor-node-metastasis (TNM) stages and tumor differentiation (P<0.001). The overall 5-year survival rate was 18.5% versus 76.9% for ctDNA EGFR mutation-positive and ctDNA EGFR mutation-negative patients, respectively. For patients with ctDNA EGFR mutation positive, the median OS and DFS were 29.00±2.55 and 19.00±2.50 months, respectively, which were both significantly better than those in the ctDNA EGFR mutation-negative subgroup (P<0.001). ctDNA EGFR mutation was an independent risk factor of OS and DFS [hazard ratio (HR) 3.289, 95% confidence interval (CI), 1.816-5.956, P<0.001; HR, 4.860, 95% CI, 2.660-8.880, P<0.001]. For stage III patients with exon 19 deletion or L858R mutations in both tissue and plasma samples, tyrosine kinase inhibitor (TKI) therapy showed significantly better OS (P=0.025) and possible DFS benefit (P=0.060) than did chemotherapy.CONCLUSIONS: EGFR mutation testing using the Scorpion-ARMS method in preoperative plasma could be a strong predictor for postoperative survival and metastasis of NSCLC patients. Thus, the subset of this population may be benefit from targeted strategies and management.

Non-invasive Detection of EGFR Deletion at Exon 19 in Non-Small Cell Lung Cancer by Real Time Diagnostic

Analytic And Clinical Validation Of An Ultrasensitive, Quantitative Polymerase Chain Reaction Assay For Egfr Mutation Analysis With Circulating Tumor Dna

A high-sensitivity detection method for plasma EGFR exon 19 deletion

Ultrasensitive and Quantitative Detection of EGFR Mutations in Plasma Samples from Patients with Non-Small-cell Lung Cancer Using a Dual PNA Clamping-Mediated LNA-PNA PCR Clamp

Exosome-based detection of activating and resistance EGFR mutations from plasma of non-small cell lung cancer patients

Establishment of a Digital PCR Platform for Detection of EGFR T790M Mutation in Plasma Circulating DNA from NSCLC Patients

Exosome-based detection of EGFR T790M in plasma and pleural fluid of prospectively enrolled non-small cell lung cancer patients after first-line tyrosine kinase inhibitor therapy

Multiplex Picoliter-Droplet Digital PCR for Quantitative Assessment of EGFR Mutations in Circulating Cell-Free DNA Derived from Advanced Non-Small Cell Lung Cancer Patients

Assessment of EGFR Mutations in Plasma from Advanced NSCLC Patients by Modified Cell-Free DNA Extraction Method and Blocker PCR Assays

Plasma epidermal growth factor receptor mutation testing with a chip-based digital PCR system in patients with advanced non-small cell lung cancer

The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR-TKI

703: PREDICTIVE VALUE OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS NASAL SWAB PCR FOR MRSA PNEUMONIA

Digital PCR analysis of plasma cell-free DNA for non-invasive detective of TKI targeted EGFR mutation in NSCLC patients

Reducing cache misses in hash join probing phase by pre-sorting strategy (abstract only)

[The Detection by Denaturing High Performance Liquid Chromatography of Epidermal Growth Factor Receptor Mutation in Tissue and Peripheral Blood from Patients with Advanced Non-Small Cell Lung Cancer].

CRISPR/Cas13a-based supersensitive circulating tumor DNA assay for detecting EGFR mutations in plasma

Comparison of EGFR mutations in blood and tumor tissue samples by allele-specific PCR

Comparison of Egfr Signaling Pathway Somatic Dna Mutations Derived from Peripheral Blood and Corresponding Tumor Tissue of Patients with Advanced Non-Small-Cell Lung Cancer Using Liquidchip Technology

Detection of epidermal growth factor receptor (EGFR) mutations from preoperative circulating tumor DNA (ctDNA) as a prognostic predictor for stage I–III non-small cell lung cancer (NSCLC) patients with baseline tissue EGFR mutations

Developing Ultrasensitive Library-Aliquot-Based Droplet Digital PCR for Detecting T790M in Plasma-Circulating Tumor DNA of Non-small-Cell-Lung-Cancer Patients

Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients.